The global neurointerventional devices market is estimated to be $1,248.5 million in 2012 and is expected to grow at a CAGR of 6.8% to reach $1,733.7 million by 2017. Aneurysm Coiling & Arteriovenous Malformation Embolization & Fistula embolization segment accounts for the largest share of the global neurointerventional devices market, followed by support devices cerebral balloon angioplasty & stenting systems and neurothrombectomy devices in 2012.
The major driving factor for these markets involves gradual technological evolution, growing ageing and obese population, rising patient pool for ischemic and hemorrhagic stroke and increasing demand for minimally invasive surgical procedures. Growing GDP and healthcare allocation are making developing countries in Asia and Latin America affordable to adapt novel medical practices for obtaining better treatment outcome. Upcoming clinical trial data is favoring the interventional procedure over neurosurgery as it offers limited hospital stays, minimal damage to surrounding healthy tissues, lesser chances of infection in post-surgical phase, minimum surgical trauma and lesser surgical scar.
North America dominates the overall neurointerventional devices market. Asia-Pacific market including India, China and Japan, and Latin America market are expected to grow at a higher pace due to the effect of growing GDP and purchasing capability of healthcare institutions in those countries. Coiling procedure and flow diversion have gained popularity in the Asia-Pacific and Latin American market.
Companies mentioned include Abbott Laboratories, Bayer Ag, Coaxia, Inc., Covidien Plc, Johnson & Johnson, Merit Medical Systems Inc., Neurointerventional Therapeutics Inc. (Nit), Nfocus Neuromedical Inc., Penumbra Inc., Reverse Medical Corporation, Stryker Corporation, Terumo Corporation, Valor Medical Inc., W.L.Gore & Associates Inc.
Key Topics Covered:
Copyright©2012 Vocus, Inc.
All rights reserved